3DBREASTCANCER · Modeling Breast Cancer in 3D Cell Culture Systems and Mice
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2012-01-01 → 2015-12-31
- Финансиране от ЕС
- 100 000 €
- Участници
- 1
- Схема
- MC-CIG
Линиите свързват координатора с партньорите.
Накратко на български
Механизмите за оцеляване на „спящи“ ракови клетки се изучават чрез 3D култури и мишани модели. Това помага да се разбере как се развиват рецидивите при рака на гърдата, за да се подобрят възможностите за лечение.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Modeling Breast Cancer in 3D Cell Culture Systems and Mice
Despite advances in therapeutic treatments, breast cancer remains the second leading cause of cancer related death in women. Mortality rates are largely attributable to typically incurable tumour recurrence at either local or distal sites, which present up to 20+ years following initially successful therapy in a large proportion (30-50%) of patients. It will be important to obtain mechanistic details of tumour therapy, escape and survival of selected cells as well as establishment of recurrent disease to improve treatment options in the clinic. However, due to the problems in tracing and isolating such cell populations from patients, model systems that faithfully re-capitulate the human disease are needed. We are employing tractable transgenic mouse models of human breast cancer to isolate and study tumour treatment and the switch from tumour dormancy to relapse. Over the past years we have established organotypic 3D cell culture of primary mouse mammary epithelial cells obtained from the above mentioned mice. This system allows monitoring of single cells within a tumour during defined tumour progression stages and gives us a tool to test new hypothesis in a relevant, readily accessible culture setting. The main aims are directed towards stages during cancer treatment that are elusive to mechanistic analysis in the clinic and include: • Interfere with the mechanisms important for survival of residual ‘dormant’ cells. • Identify the molecular properties that allow surviving-residual cells to progress towards recurrence
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Breast cancer is one of the most common malignancies among women in the western world. In the last two decades, major advances have been made in our understanding of breast cancer that have resulted in a decline in breast cancer mortality. To advance these improvements, research efforts need to be directed to a series of areas, including breast cancer genetics and identification of new targets for therapy.Accordingly, the proposed research aims to characterize mammary cells during different stages of carcinogenesis, targeted treatment and during their dormant period that might lead to tumor relapse:•We will delineate cooperating lesions in breast cancer to develop better strategies for targeted therapy.•Our approach to understand the origin of tumor initiating cells and how and why they differ from normal breast stem cells will open new avenues in tumor treatment and prevention.•Characterization of the residual cells after treatment will greatly improve our understanding of the mechanisms of oncogene dependence and may lead to more effective therapeutic strategies to prevent breast cancer relapse.To investigate these objectives, we will utilize tractable in vivo mouse mammary tumor models in parallel with 3D cell culture systems of primary mammary cells derived from these animals. This novel, combined approach allows to retrieve more detailed mechanistic insights with respect to cellular organization, position and fate of specialized cells within a mammary acinus and -at the same time- to follow the in vivo model for overall phenotypes.The EMBL Mouse Biology Unit offers me the unique chance to implement these novel approaches in the European Research Area (ERA). Employment of sophisticated 3D cell culture systems in combination with transgenic mouse models, are expensive. The FP7-PEOPLE-2011-CIG award will contribute to address the outlined objectives and will allow to perform experiments that we view as a potent preclinical approach.
Оригинален текст от CORDIS (на английски).
Участници
- EUROPEAN MOLECULAR BIOLOGY LABORATORY · HeidelbergКоординаторГермания
Връзки
Данни: CORDIS, © Европейски съюз